ArticleTherapeutic delivery2025
Preclinical toxicological evaluation of adjunct dementia medicinal supplement (PMCV002) in Wistar rats: from bench to clinical trial series.
Article in Therapeutic delivery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundConsidering unmet clinical needs in the dementia therapeutics world, PCMCV002 was developed as a cheap and easily accessible adjunct therapy option. It is a combination of amino acids, vitamins, and essential nutrients formulated in a best-fit complex medicinal food supplement as an adjunct therapy to the already established dementia therapies.
aimThe aim of this study is to evaluate the sub-acute preclinical toxicity profile of PCMCV002 in Wistar rats. MATERIALS/
methodPMCV002, ketamine, Photoelectric colorimeter model AE 11D (Erma Inc. Japan), Hematology analyzer (Sysmex USA), hematocrit, centrifuge, spectrophotometer, weighing balance, cotton wool, scissors, animal cages, plastic containers, plain and heparinized plastic bottles. The study involved hematology, hepatorenal and electrolytes changes and histological evaluation 28 days postdosing daily with PCMCV002 using OECD test Guideline 407 (2008).
conclusionsThe findings following a 28-day administration of PMCV002 revealed that it is relatively nontoxic in rats, as no obvious harmful effects were noted on hematological and biochemical indices. The histo-architecture of the brain, heart, liver, and kidneys following a 28-day administration of PCMCV002 to the test rats did not show any significant pathologic changes. All these indicate a quite safe medicinal product, coupled with maximum tolerable dose as high as 5000 mg/kg.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.